Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Aschaffenburg – page 11

1 096 clinical trials in Aschaffenburg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aschaffenburg at a glance
1 096
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 096 trials in Aschaffenburg

Open in trial search

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:Novartis Pharma AG

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Aschaffenburg

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on acute myeloid leukemia and chronic lymphocytic leukemia, evaluating novel therapeutic approaches including targeted therapies and combination treatments. Studies examine innovative drug combinations to improve patient outcomes in various blood cancers.

  • FLT3-mutation targeted therapies
  • Chemotherapy optimization
  • Novel drug combinations

Multiple trials investigating treatments for both newly diagnosed and relapsed/refractory patients.

02 Breast Cancer Research

Advanced studies in hormone receptor-positive breast cancer, particularly focusing on metastatic disease. Investigations include new combination therapies and targeted treatments for patients with specific genetic mutations.

  • ESR1-mutation treatments
  • CDK4/6 inhibitor combinations
  • Endocrine therapy resistance

Research emphasizes personalized treatment approaches based on molecular profiles.

03 Respiratory Medicine

Innovative research in severe asthma treatment, particularly focusing on patients with eosinophilic phenotype. Studies evaluate new biological therapies and compare their efficacy with existing treatments.

  • Anti-IL-5/5R therapy
  • Long-term efficacy studies
  • Phenotype-specific treatments

Trials aim to improve long-term management of severe respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.